Dianthus Q2 FY26 net loss widens to $50.22 million; R&D expenses climb 85.47% to $48.69 million

Reuters2026/08/04 20:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Dianthus Therapeutics posted a Q2 net loss of USD 50.22 million, widening from USD 31.63 million a year earlier.
Revenue rose to USD 761,000 from USD 193,000; R&D expenses climbed to USD 48.69 million from USD 26.25 million.
G&A costs increased to USD 13.56 million from USD 8.87 million; cash, cash equivalents and investments totaled about USD 1.2 billion at June 30.
Phase 3 EMERGE trial of claseprubart in generalized myasthenia gravis began in June, with top-line results expected in 2H 2028.
CAPTIVATE Phase 3 CIDP interim analysis showed a 75% response rate in the first 40 Part A completers; MMN Phase 2 top-line data are due in December 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608041601PRIMZONEFULLFEED9803229) on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Dianthus Q2 FY26 net loss widens to $50.22 million; R&D expenses climb 85.47% to $48.69 million

You may also like

Crypto prices